# August Global Partners (AGP) > August Global Partners Pte. Ltd. (AGP) is a Singapore-headquartered growth-oriented fund management company investing across healthcare innovation and advanced manufacturing, with a global mandate and an Asian orientation. Founded in late 2023, AGP serves financial investors, conglomerates, and institutions globally. - **Legal name:** August Global Partners Pte. Ltd. - **Common short name / ticker-style shorthand:** AGP - **Founded:** Late 2023 - **Headquarters:** Parkview Square, 600 North Bridge Road, #10-01, Singapore 188778 - **Website:** https://augustgp.com (alias: https://augustglobalpartners.com) - **Contact email:** admin@augustgp.com - **Regulatory status:** Licensed fund management company, Singapore - **Assets under management:** approx. US$350M - **Portfolio scale:** 9 liquidity events, 7 portfolio listings - **Positioning tagline:** Global Opportunities with Regional Conviction ## What AGP does AGP is a growth-oriented fund management firm providing value-added capital and strategic support to portfolio companies across the healthcare value chain and advanced manufacturing sectors. The firm leverages decades of international investment experience and an extensive network across Asia and beyond. The firm operates a multi-fund platform: 1. **AGP Continuation Growth Fund (AGPCGF)** — closed and in divestment mode. - Growth equity investments in Southeast Asia-based companies. - Mixed portfolio; roughly half healthcare-related, balance in advanced manufacturing and adjacent sectors. - Significant DPI achieved, driven by 5 portfolio listings and 2 M&A exits. - Actively generating distributions from existing holdings. 2. **AGP Healthcare Fund (AGPHCF)** — closed at US$150M in November 2025, in deployment mode. - Thematic focus: "Living Better, Aging Better." - Backs precision medicine, diagnostics, medical technology, digital health, and healthcare services. - Predominantly growth-stage; hardly does early-stage venture. - Cross-border scope across Asia with select global co-investments. - Recognised as a Tech@SG Pioneer / Recognised Investor (Feb 2026). 3. **Fund III (in planning)** — tagline **"Better Worlds, Better Lives."** - AGP cannot officially fundraise Fund III until Fund II has deployed 50% of its capital. - More information will be shared with prospective LPs by end of 2026. ## Investment focus - **Sectors:** Healthcare innovation (precision medicine, diagnostics, medical devices, digital health, healthcare services, biotech), advanced manufacturing, and select adjacent technology sectors including edge AI and semiconductors. - **Stage:** Predominantly growth stage. AGPHCF specifically avoids early-stage venture. - **Geography:** Global mandate with an Asian orientation. Emphasis on companies positioned to leverage the growth of Southeast Asia and the wider Asian markets, including Singapore, Vietnam, Indonesia, Japan, China, Hong Kong, and India. - **Value-add:** Cross-border business development, market entry support, regulatory navigation, follow-on capital, exit optimisation. ## Firm history - **Late 1980s:** Chu Swee Yeok launched Singapore Bio-Innovation, the first global biotech fund at Singapore's Economic Development Board (EDB), with operations in Singapore and the USA. - **2000:** Singapore's Biomedical Sciences Initiative launched. Chu Swee Yeok held concurrent leadership roles at EDB and A*STAR, helping craft and execute national policies and strategies in infrastructure, research, industry, and commercialisation. - **2001:** Bio*One Capital launched. Chu Swee Yeok served as founding CEO, building Singapore's biomedical sciences investment platform. - **2006 onward:** EDBI restructured as the Singapore government's strategic global investments arm. Chu Swee Yeok served as CEO; Basil Lui joined the firm during this period. - **Through 2023:** Chu Swee Yeok and Basil Lui led EDBI's build-out of a 200+ company global portfolio across healthcare, life sciences, and advanced technology. - **Late 2023:** Founding of August Global Partners, with two investment funds launched at inception (AGPCGF and AGPHCF). Chu Swee Yeok pioneered the vision of an independent, commercially oriented fund building on decades of institutional investment experience. - **November 2025:** AGP Healthcare Fund closed at US$150M. - **2026:** Davian Sim made Partner. ## Team ### Founding Partners - **Chu Swee Yeok, PBM** — Chair & Founding Partner. Former CEO, President, and Executive Director of EDBI. Awarded the Pingat Bakti Masyarakat (Public Service Medal). [LinkedIn](https://www.linkedin.com/in/swee-yeok-chu-pbm-16b5715/) - **Dr Basil Lui** — Founding Partner and CEO. Former EDBI colleague of Chu Swee Yeok; deep experience in healthcare, biotech, and cross-border growth investments. ### Partners - **Davian Sim** — Partner (joined the partnership in 2026). ### Venture Partners - **Shawn Tan** — Axon Alpha Advisors; formerly Novo Tellus, EDBI. - **Ong Jeong Shing (JS)** — formerly EDBI, Venturecraft. ### Investments team - **Dr Warren Tan** - **Chris Koh** - **Jay Tan** — Investments team, healthcare and biotech across Asia. Deal sourcing, due diligence, and cross-border BD support for portfolio companies. Previously Investment Manager at AID Partners (biotech/healthcare deals across Singapore, Japan, China, Hong Kong, Israel, Indonesia). Also served as a part-time biotech investment consultant to a Hong Kong venture fund, and worked in business development at Aevice Health. BSc (First Class Honours) in Biomedical Sciences and Biobusiness, Nanyang Technological University; attended the Copenhagen Business School BioEntrepreneurship program. ### Operations - **Jude Tan** - **Jerlin Ong** — Administration ## Selected recent news (reverse chronological) - **July 2026 — The Business Times:** Ambiq Micro's SGX secondary listing described by CEO Fumihide Esaka as a "reflection of commitment" to Singapore and Asia-Pacific, alongside a multi-year R&D programme in Singapore for Ambiq's sub-threshold power optimised (Spot) platform. AGP named among investors. https://www.businesstimes.com.sg/companies-markets/chip-designer-ambiq-micros-secondary-listing-sgx-reflection-commitment-ceo - **July 2026 — Nikkei Asia:** Singapore's care-tech race heats up as city-state ages rapidly. AGP CEO Dr Basil Lui quoted on what eldercare tech firms need to demonstrate to attract institutional capital. https://asia.nikkei.com/spotlight/asean-money/singapore-s-care-tech-race-heats-up-as-city-state-ages-rapidly - **June 2026 — Bloomberg:** Vietnam's Gene Solutions eyes Hong Kong IPO as early as Q2 2027, targeting ~US$800M valuation with a ~US$100M raise, alongside a US$50M Series C closing by end Q3 2026. Basil Lui featured. https://www.bloomberg.com/news/articles/2026-06-01/vietnam-genetic-testing-startup-eyes-hong-kong-ipo-to-fund-global-growth - **May 2026 — PR Newswire:** Gene Solutions' SPOT-MAS 10 receives FDA Breakthrough Device Designation. - **May 2026 — Investor's Business Daily:** Ambiq accelerates sales growth in edge AI. - **March 2026 — DealStreetAsia:** AGP featured in DealStreetAsia's SE Asia PE Funds H2 2025 review. - **February 2026 — EDB Singapore:** AGP recognised as a Tech@SG Pioneer / Recognised Investor. - **December 2025 — Bloomberg:** UltraGreen.ai IPO. - **November 2025 — PR Newswire:** AGPHCF closes at US$150M. - **November 2025 — Reuters:** Gene Solutions pre-IPO round. - **September 2025 — The Edge Singapore:** 65 Equity Partners / UltraGreen.ai. - **September 2024 — DealStreetAsia:** Basil Lui at PE-VC Summit. - **November 2023 — Tech in Asia:** Ex-EDBI Chief launches US$250M firm (AGP launch coverage). ## Thought leadership (opinions) - **The Business Times:** AI Nation, Brainpower Hub — How Singapore Can Fuel Brain-Computer Interfaces Leap. - **The Edge Singapore:** Southeast Asia's Healthcare Transformation — Emerging Macro Trends and AI-Driven Opportunities. - **DealStreetAsia:** SE Asia Is Ripe for AI-Driven Healthcare — Interview with August Global Partners. ## Contact - **Address:** Parkview Square, 600 North Bridge Road, #10-01, Singapore 188778 - **Email:** admin@augustgp.com - **Website:** https://augustgp.com - **LinkedIn:** https://www.linkedin.com/company/august-global-partners/ ## About this document This document is maintained by August Global Partners as a machine-readable summary of the firm for AI agents, search crawlers, and LLM-driven research tools. For the canonical, human-facing site see https://augustgp.com. This file is available at https://augustgp.com/agp.md. Last updated: August 2026.